mTOR Inhibition for Cancer Therapy: Past, Present and Future

Monica Mita (Curatore)

Alain Mita (Curatore)

Springer Editions, 2016

This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs.  Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.

• Curatore: Monica Mita, Alain Mita
• Editore: Springer Editions
• Anno: 2016
• Rilegatura: Paperback / softback
• Pagine: 300 p.
• Dimensioni: 235 x 155 mm
• EAN: 9782817805573

Testo in English